Yes - the risk discount decreases after Phase 3 results (assuming they are strong) and then even more after approval.
It is important to note this comparison is comparing Daybue's value to Skyclarys, not NNZ-2591. Whilst NNZ-2591 is less developed we all know that it has shown strong efficacy to date in multiple indications, something that cannot be said for Skyclarys or Daybue (afaik)* all whilst having a better safety profile compared to Trof. Even if you look at PMS and PH only the patient population sizes are multiple of Rett or Friedreich's ataxia.
* Trof results for Fragile X weren't that speculator from memory, and we know that Trof for TBI was a fail. To date all NNZ-2591 results whilst smaller trials show far stronger efficacy signals and Trof still was ultimately approved and has made a real difference for patients lives!
NEU Price at posting:
$13.35 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)